340binformed.org

Your Free Source for 340B News and Commentary

  • About us
  • Advertise
  • Contact
  • 340B Health

HHS Reopens Comments for 30 Days on 340B Pricing and Monetary Penalty Regulation

Wants input on penny pricing, 340B prices for new drugs, knowing-and-intentional standard for penalties 

April 18, 2016—The Department of Health and Human Services is giving 340B stakeholders an extra 30 days, until May 19, to comment on three aspects of its proposed 340B program rule setting standards for calculating ceiling prices and implementing civil monetary penalties for drugmakers that knowingly and intentionally overcharge for 340B drugs. … [Read more...]

HRSA Sends OMB Proposal to Amend 340B Pricing Agreement

Public comments due by May 9 

April 8, 2016—The Health Resources and Services Administration has taken another step toward amending the 340B Pharmaceutical Pricing Agreement to include drug manufacturer program integrity provisions in the Affordable Care Act. … [Read more...]

Price of Insulin More Than Doubled Since 2002

Study adds more fuel to controversy over rising drug prices 

April 7, 2016—Drug manufacturers more than doubled the price of insulin – which people with Type 1 diabetes need to stay alive – between 2002 and 2013, according to new research published in JAMA. … [Read more...]

CMS Gives Drugmakers Extension to Report 5i AMP Per Final Rule

July 1 is the new deadline 

April 6, 2016—The Centers for Medicare & Medicaid Services is giving drug manufacturers a three-month extension to begin calculating and reporting, in accordance with new federal regulations, the average manufacturer price for "5i" inhalation, infusion, instilled, implanted or injectable drugs that are not generally dispensed through retail community pharmacies. … [Read more...]

Drugmakers Took Hefty Price Increases Since 2011

Charges for top 10 drugs more than doubled in some cases 

April 5, 2016—Prices for four of the nation's 10 most widely used prescription drugs more than doubled since 2011 and price hikes for the other six ranged from 96 percent to 54 percent, a Reuters wire service analysis of proprietary data has found. … [Read more...]

Lawmakers Want NIH to Rein in Cancer Drug’s Steep Cost

 

March 31, 2016—Twelve Members of Congress are urging the National Institutes of Health to respond favorably to a petition to use its statutory authority to lower the price of an expensive prostate cancer drug developed with taxpayer support.    … [Read more...]

Physicians Group Calls for Action on Rising Drug Prices

Internists back tougher regulation of drug industry 

March 29, 2016—The nation's second-largest physician association is offering policymakers a multi-point plan to slow the rising cost of prescription drugs.  … [Read more...]

« Previous Page
Next Page »

LATEST ARTICLES DELIVERED

Get new article alerts via email.

This field is required.

Check your inbox or spam folder now to confirm your subscription.

FOLLOW | SHARE | LIKE

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

340B Health Twitter

Twitter feed is not available at the moment.

RSS feed: 340B Employed 340B Employed

  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Specialist | Vail Health November 17, 2026
  • Pharmacy Manager, 340B Program | Tufts Medical Center November 11, 2026
  • 340B Program Pharmacy Manager | Allies for Health + Wellbeing November 10, 2026

Copyright © 2026 · 340B Health